STOCK MARKET BSE NSE

Molnupiravir could be promising drug to treat mild cases of Covid, say doctors

The data was drawn from 775 patients and reported that 7.3 percent of patients who received the drug were either hospitalized or died by day 29, as compared to 14.1 percent of the placebo patients.

Published: 04th October 2021 01:10 PM  |   Last Updated: 04th October 2021 01:10 PM   |  A+A-

A Covid-19 patient on an oxygen support inside a Covid-19 care center set up at Shehnai Banquet in New Delhi on Monday

A Covid-19 patient on an oxygen support inside a Covid-19 care center set up at Shehnai Banquet in New Delhi. (Photo | Shekhar Yadav, EPS)

By Express News Service

BENGALURU: The experimental COVID-19 drug Molnupiravir could be promising in treating Covid patients with mild to moderate symptoms, going by the announcement made on October 2 by the company, Merck and Ridgeback Biotherapeutic, after completing the Phase 3 trials.

According to the preliminary data available, doctors say this could be useful in treating COVID-19 patients in the early stages of the disease as the company reported a 50 percent drop in hospitalization and death.

"While we have medicines for moderate to severe patients, for mild patients we are still struggling without a proper drug. If the data is correct, this medicine could be a game-changer. Due to positive results, the trial was stopped early. It can be taken orally in the outpatient department, without requiring admission," said Dr Chinnadurai R., Lead Consultant, Department of Critical Care, Aster RV Hospital.

The data was drawn from 775 patients and reported that 7.3 percent of patients who received the drug were either hospitalized or died by day 29, as compared to 14.1 percent of the placebo patients.

"Molnupiravir induces 'lethal mutagenesis' thereby reducing viral replication. 775 is a small number and the study is yet to be peer-reviewed and published. We have to see the clinical benefit on the ground and also wait for the regulatory approval. Unlike Remdesivir, it need not be injected," said  Dr. Anoop Amarnath, Head, Scientific Board and Chairman-Geriatric Medicine, Manipal Hospital and member of the state's COVID-19 Critical Care Support Team.

Further studies have to be done but the early results are encouraging, said Dr Suhas HS, Consultant Pulmonologist at Columbia Asia Hospital.

"The company intends to approach the US Food and Drug Administration for Emergency Use Authorization (EUA) but we need to see how cost-effective it is in the Indian setting. Meanwhile, the COVID-19 vaccine remains the most effective way to bring down the severity of disease and mortality, and must be actively promoted," Dr. Suhas added.

In India, five companies are conducting trials for this drug - Cipla, Dr. Reddy's, Emcure, Sun Pharma and Torrent.
 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp